Company news

Happy Holidays from ChemDiv Inc

Investigators from John Byrd's Lab at University of Cincinnati Presented Non-Clinical Summary Data for The Best-in-Class Selective BCL2 Inhibitor Clinical Candidate Developed by Eilean Therapeutics in...

ChemDiv Presented Non-Clinical Summary Data for The Best-in-Class Selective FLT3 Clinical Candidate at the 65th ASH Annual Meeting and Exposition with Its Partners and Sponsors ...

Institute of Virology, Hannover Medical School, reported about notable results in their drug discovery projects, using small molecule libraries designed and provided by ChemDiv Inc.

Discovery on Target (DOT) conference will be held on September 25-28, 2023. It highlights advances in current and emerging “hot” targets and technologies

Coimbra, Portugal - ChemDiv Inc, a global leader in drug discovery and drug development solutions, shares the progress in the development of its cutting-edge biology facility at Biocant Park

Join ChemDiv,Inc at the International Helmholtz Drug Discovery Conference (HDDC) 2023 that will take place in Germany www.helmholtz-hzi.de/de/hddc2023 (May 15 to 16, 2023 – Braunschweig, Germany...

Roman Timakhov, M.D., Ph.D, Research Director, ChemDiv Inc presented "First Principle Concept in Designing Small Molecules for Targeting RNA Expansion Repeats”

The warmest congratulations on The New Year and Christmas from San Diego

A new dedicated research group will be created on the Jacobs University Bremen campus, merging ChemDiv’s extensive drug discovery expertise and technological platforms with advanced fundamental rese...

To our pharma and biotech customers and suppliers, we want to assure you that ChemDiv Inc is keenly aware of and strongly opposed to the current Russia military actions in Ukraine. ChemDiv Inc is a ...